|  | Entry | 7 to 21 days after entry | 13 weeks from entry (allowing for subsequent 14 days) | 26 weeks from entry (allowing for subsequent 30 days) | 52 weeks from entry (allowing for subsequent 30 days) |
---|---|---|---|---|---|---|
Kyoto University | HADS assessed through telephone | x | Â | x | x | x |
Allocation guessed by raters | Â | Â | x | x | x | |
CRC | Informed consent, registration to EDC, information about allocated group | x | Â | Â | Â | Â |
Socio-demographic variables (such as age, academic status, marital status and partners) | x | Â | Â | Â | Â | |
Concentrations of omega-3 fatty acids in membrane of RBC, oxidative stress, and antioxidant status | x | Â | x | Â | Â | |
(2 hospitals) | Â | (2 hospitals) | ||||
Participants’ input through EDC | PHQ-9 | x |  | x | x | x |
GAD-7 | x | Â | x | x | x | |
ISI | x | Â | x | x | x | |
MBI | x | Â | x | x | x | |
BSI | x | x | x | x | x | |
HPQ | x | Â | x | x | x | |
EQ-5D | x | Â | x | x | x | |
Numbers of incidents and accidents | x | Â | x | x | x | |
Numbers of visits to clinics | x | Â | x | x | x | |
Numbers of absent days due to any reason | x | Â | x | x | x | |
History of taking psychotropic drugs | x | Â | x | x | x | |
Adverse events | Â | x | x | x | x |